BMO Capital analyst Kostas Biliouris maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $57.00.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Beam Therapeutics’ promising advancements in their BEAM-302 treatment for AATD. The treatment demonstrated a strong efficacy by exceeding the protective threshold of 11uM, achieving a mean total-AAT of 12.4uM at a 60mg dose. This outcome suggests that a higher dose could further improve efficacy, potentially reaching 15-17uM, while maintaining a clean safety profile without significant adverse effects.
Furthermore, the safety of BEAM-302 alleviates concerns regarding acute reactions, which is a positive indicator for its continued development. The treatment’s ability to produce functional AAT through bystander edits addresses key investor concerns, and the dose-response relationship observed supports the potential for higher dosing. These factors, combined with the strong data and optionality for future dose adjustments, position Beam Therapeutics favorably in the competitive landscape of gene editing and RNA editing technologies.
Biliouris covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Sarepta Therapeutics, and Beam Therapeutics. According to TipRanks, Biliouris has an average return of -11.0% and a 33.66% success rate on recommended stocks.
In another report released on March 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com